Semaglutide Added 100 Days to Old Mice, Then Beat Eating Less At Its Own Game
A new mouse study out of UC Berkeley found that starting semaglutide late in life added roughly 100 days of median lifespan, improved muscle function and sharpened spatial memory. That headline number is not the interesting part. The interesting part is what the researchers compared it against.
- UC Berkeley researchers started semaglutide in 20 month old female mice, roughly late middle age, and got about 100 extra days of median lifespan.
- The treated mice also showed better muscle function, better spatial memory and reduced inflammatory gene activity.
- The real test: semaglutide compared directly against a 24 percent calorie restricted diet matched to what the treated mice actually ate. Most measures moved similarly in both groups.
- The semaglutide mice improved past their own starting baseline on memory and blood sugar control and kept a normal metabolic rate, while the calorie restricted mice slowed down. This is mice only, female mice only, and the researchers say it does not show anything about human lifespan.
What the Berkeley team did
The researchers gave semaglutide to 20 month old female mice, the rough equivalent of starting treatment in late middle age, for three months. Compared with untreated mice of the same age, the treated animals showed better muscle and cognitive function, along with gene activity changes pointing to reduced inflammation and slower decline in tissue repair capacity. In a separate group treated until death, median lifespan ran nearly 100 days longer than untreated controls.
The control group that makes this more than a headline
Semaglutide suppresses appetite, so the obvious objection to any benefit is that it is just calorie restriction delivered by injection. Rather than wave that off, the team ran the comparison directly. For five months, one group of 20 month old females received semaglutide while a second group was put on a 24 percent calorie restricted diet calibrated to match what the treated mice actually ate. On most physiological measures, the two groups moved similarly. But the semaglutide mice improved beyond their own starting baseline on exploratory behavior, spatial memory and blood sugar maintenance, and they kept a normal metabolic rate where the calorie restricted mice slowed down. That is the argument that GLP1s may act on aging through a pathway calorie restriction does not use. That last detail is the mechanistic tell. Calorie restriction extends lifespan partly by slowing metabolism down. Semaglutide appears to be doing something else. The paper's corresponding author, Danica Chen, frames this carefully as a possible independent biological pathway worth investigating further, not as a settled conclusion.
An hourglass, used here as an aging and lifespan metaphor, not imagery from the study.
Suohros
Illustrative, a lifespan metaphor, not the study's own mice or drug.
Calorie restriction extends lifespan partly by slowing metabolism down. Semaglutide appears to be doing something else.
Honest caveat
This is mice, and only female mice. No male arm is reported in the available coverage, and sex specific lifespan effects are common in aging research, so this should never be reported as semaglutide extends lifespan without that qualifier. Group sizes were not stated in the coverage, and the Nature paper itself was not retrieved first hand, which is what keeps this at a B rather than higher grade of evidence. The researchers state explicitly that these findings do not show that GLP1 drugs extend human lifespan, and no human trial of GLP1s in healthy older adults without obesity or diabetes has been run. The two interventions also overlapped on most outcomes in this study, so calling semaglutide entirely independent of calorie restriction would overstate the finding. The honest read is that they diverged on a specific, real subset of measures, not that they diverged on everything.
What this means for you
This is not a reason to start or continue semaglutide for a longevity benefit that has only been shown in old female mice. What it is genuinely useful for is understanding what a well designed control group buys you. Most coverage of this study will lead with the 100 extra days. The more useful habit to build as a reader is asking what a study ruled out before it ran the number you saw in a headline. It is also a reminder that the comparator here, eating meaningfully less, is itself a validated longevity intervention in mice, with its own real tradeoff this study surfaces plainly: the calorie restricted animals lost the ability to keep their metabolic rate steady, something people rarely hear about when calorie restriction gets pitched as a free longevity hack.
Primary sources
Common questions
Does this mean semaglutide extends human lifespan?
No, and the researchers say so directly. This study was done in mice, and only female mice at that. No male arm is reported, and sex specific lifespan effects are common in aging research, so a female only result should never be reported as semaglutide extends lifespan without that qualifier. No human trial of GLP1 drugs in healthy older adults without obesity or diabetes has been run yet.
Is this just the effect of eating less, since semaglutide suppresses appetite?
That was the obvious objection, and the researchers tested it directly rather than waving it away. They compared semaglutide against a 24 percent calorie restricted diet matched to exactly what the treated mice ate. Most measures moved similarly in both groups, but the semaglutide mice improved beyond their own starting point on memory and blood sugar control and kept a normal metabolic rate, while the calorie restricted mice slowed down. The two interventions overlapped on most outcomes, so calling semaglutide totally independent of calorie restriction would be an overclaim, but they did diverge on a real, specific subset.
What does the control group in this study actually prove?
It proves the researchers took the most obvious counterargument seriously instead of assuming it away. Because semaglutide suppresses appetite, any benefit could simply be calorie restriction in a different form. By matching a second group's diet to exactly what the treated mice ate and comparing the two head to head, the team could see where the drug tracked calorie restriction and where it did not, which is a stronger design than either result on its own.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.